What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best affordable healthcare stocks to buy now. Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced on December 24 that S&P Global Ratings upgraded the company’s long-term issuer credit rating to ‘BB+’ from ‘BB’ with a stable outlook. Moody’s Ratings Agency also affirmed the company’s B1a rating, revising its outlook to positive from stable.

Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge Funds is Buying

Management stated that the upgrades mark a notable milestone in Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) advancement towards attaining investment-grade status. S&P noted that the company’s adjusted leverage declined to 4.4x as of September 30, 2025, and is anticipated to drop below 4.25x in the coming quarters and meet the threshold for the higher rating. The agency also cited Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) business strength, liquidity profile, and financial discipline, with it bouncing back to revenue growth following five years of declines with support from solid performance in branded medicines and stabilization in generics.

In a separate development, Piper Sandler lifted the price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) to $40 from $30 on December 22 and reaffirmed an Overweight rating on the stock. The firm cited further multiple expansion, stating that the company’s peer group is undergoing evolution with the mix continually shifting towards novel brand assets. It clarified that the larger cap biopharma group is becoming a more appropriate peer group for Teva Pharmaceutical Industries Limited (NYSE:TEVA). Similarly, Goldman Sachs lifted the price target on the stock to $35 from $31, keeping a Buy rating on the shares.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, produces, and sells medicines. Its operations are divided into the US, Europe, and International Markets geographical segments. Each business segment covers the entire product portfolio in that region, including specialty, generics, and over-the-counter (OTC) products.

While we acknowledge the potential of TEVA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEVA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.